Navigation Links
ZymoGenetics Reports Results From Atacicept Phase 1b Clinical Trial,in B-Cell Chronic Lymphocytic Leukemia

SEATTLE, June 04, 2007 /PRNewswire-FirstCall/ -- ZymoGenetics, Inc. today announced that interim findings were presented from a Phase 1b clinical trial with atacicept in B-cell chronic lymphocytic leukemia (B-CLL) at the American Society of Clinical Oncology (ASCO) 2007 annual meeting. The study included intravenous administration of higher doses than had been tested in previous studies.

"We found that atacicept was well-tolerated and biologically active at all dose levels in this study, consistent with the results of our other clinical trials," said Douglas E. Williams, Ph.D., Executive Vice President and Chief Scientific Officer of ZymoGenetics. "Together with our partner Merck Serono, we will assess the results of this and our other B-cell malignancy studies, once the studies are complete, to see whether the data support moving forward in these indications."

Atacicept in B-CLL Study Design and Results

In a Phase 1b open-label, dose escalation study, 15 patients with refractory or relapsed disease were given weekly intravenous doses of atacicept ranging from 1 mg/kg to 20 mg/kg, for five weeks. Treatment with atacicept was well tolerated at all dose levels in the study. No dose limiting toxicities or serious adverse events related to study drug have been reported to date. Among the six patients given 10 mg/kg and 15 mg/kg, three (50%) showed signs of disease stabilization, using National Cancer Institute-sponsored Working Group criteria, during the treatment period. Prior to atacicept treatment, all of these patients had rapidly increasing leukocyte counts. One patient, who received 10 mg/kg, exhibited stable disease for over six months.

Biological activity of atacicept was demonstrated in these patients by reduced immunoglobulin (Ig) concentrations after treatment at all dose levels. Mean IgA, IgG and IgM concentrations decreased by 20%, 22% and 15% from baseline, respectively, af
'"/>




Page: 1 2 3

Related medicine technology :

1. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
2. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
3. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
4. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
5. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
6. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
7. Cytochroma Reports Positive Phase I Clinical Data for CTA018 Injection
8. Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension
9. Columbia Laboratories Reports Positive Results from Multi-dose Pharmacokinetic Study of Vaginally-administered Lidocaine
10. CytRx Reports Promising Data from Its Open-Label Extension Clinical Trial of Arimoclomol in ALS
11. Affymax Reports Phase 2 Clinical Dose Ranging Results of Once-Per-Month Hematide for the Treatment of Anemia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/12/2017)... and NEW YORK , Sept. 12, 2017   ... for global supply chains, has published the first annual edition of its ... of more than 20,400 companies evaluated by EcoVadis, based on Scorecard Ratings ... 2016. ... CSR Risk & Performance Index ...
(Date:9/12/2017)... 2017  ValGenesis Inc., the global leader in ... to announce the appointment of Dr. Ajaz ... of Directors and Chairman of Advisory Board beginning ... companies to manage their entire validation lifecycle process ... this process. Furthermore, ValGenesis VLMS enables rigorous compliance, ...
(Date:9/9/2017)... 2017 Dealmed Medical Supplies, New ... equipment, supplies, drugs, vaccines, and specialty medical products and ... agreement to acquire Vantage Medical Supplies, a major distributor ... Holtsville, New York . ... emerging medical practices, will operate under the Dealmed name ...
Breaking Medicine Technology:
(Date:9/24/2017)... ... September 24, 2017 , ... “The Gospel Truth Of The Bible: The Other Sheep”: ... Truth Of The Bible: The Other Sheep” is the creation of published author, Maurice Caines. ... the West Indies. He has been a member of the Seventh-day Adventist Church for ...
(Date:9/22/2017)... ... September 22, 2017 , ... MEDIA OPPORTUNITY: , Save Our ... interview citizens on why they are rallying against Mayo Clinic. Specifically, media can talk ... against Dr. Noseworthy’s (CEO) decision to close the Albert Lea hospital. , The rally ...
(Date:9/22/2017)... York (PRWEB) , ... September 22, 2017 , ... ... and assembles Passive House buildings, and Richard Pedranti Architect (RPA), a ... House from the strategic partner’s Solsken Line of Model Homes . Independently, ...
(Date:9/22/2017)... ... September 22, 2017 , ... Happy Living’s mission - to ... carries it into the entertaining and delicious worlds of theatre and wines. ... Happy Living) convinced him to turn his play into a book. The Greener The ...
(Date:9/22/2017)... ... September 22, 2017 , ... ... rooms is celebrating the one year anniversary of its Houston-Fallbrook facility. , ... Dr. Otinwa, Facility Medical Director of First Choice Emergency Room Houston-Fallbrook. “It has ...
Breaking Medicine News(10 mins):